Late Breaking Abstracts

01. Cervical cancer

#142 AN INTERNATIONAL RANDOMIZED PHASE III TRIAL Comparing Radical Hysterectomy and Pelvic Node Dissection (RH) vs Simple Hysterectomy and Pelvic Node Dissection (SH) in Patients with Low-Risk Early-Stage Cervical Cancer (LRESCC)

1Marie Plante, 2Janice Kwon, 3Sarah Ferguson, 4Vanessa Samouilhan, 5Govan Lal Ferron, 6Amandine Maudard, 7Car De Kron, 8Willemin van Driel, 9John Tidy, 10Karim Williamson, 11Sven Mahner, 12Stefan Kommos, 13Frederic Goffin, 14Karl Tamussino, 15Brynhildur Eyjólfsdóttir, 16Jae-Weon Kim, 17Noreen Gieson, 18Lori Brotto, 19Dongsheng Tu, 20Lois E Shepherd.

1Centre Hospitalier Universitaire de Quebec, Quebec, Canada; 2University of British Columbia, Vancouver, Canada; 3Prixess Margaret Hospital, Toronto, Canada; 4Centre Hospitalier de l’Université de Montréal, Montreal, Canada; 5Institut Claudius Regaud, IUCT-Oncoptole, Toulouse, France; 6Gustave Roussy Cancer Center, Villejuif, France; 7Leiden University Medical Center, Leiden, Netherlands Antilles; 8Netherlands Cancer Institute, Amsterdam, Netherlands Antilles; 9Royal Hallamshire Hospital, Sheffield, UK; 10Warrington University Hospitals, UK; 11LMU University Hospital, Munich, Germany; 12Tuebingen University Hospital, Munich, Germany; 13CHU de Liege, Liege, Belgium; 14Medical University of Graz, Liege, Austria; 15Oslo University Hospital, Graz, Norway; 16Gusol National University College of Medicine, Oslo, South Korea; 17St James’ Hospital, Seoul, Ireland; 18University of British Columbia, Dublin, Canada; 19Canadian Cancer Trials Group, Queen’s University, Vancouver, Canada; 20Canadian Cancer Trials Group, Queen’s University, Kingston, Canada

Introduction/Background The objective of this non-inferiority phase III prospective randomized trial was to compare RH to SH in women with LRESCC.

Methodology Women with LRESCC defined as stage IA2 or IB1 disease with lesions ≤2cm were randomized to RH or SH. The primary endpoint was pelvic recurrence rate at 3 years (PRR3). Primary intention to treat (ITT) analysis included all patients randomized. Secondary endpoints included extra-pelvic relapse-free survival (EPRFS), overall survival (OS) and patient reported outcome.

Results 700 women were enrolled from December 2012 to November 2019. Median age was 44 (24-80); 91.7% were stage IB1 and 61.7% were squamous histology. On final pathology, lymph node metastasis occurred in 3.7% (3.3% SH and 4.4% RH), positive margins in 2.9% (2.9% SH and 4.1% RH), and lesions >2cm in 4.25% (4.4% SH and 4.1% RH). A total of 8.8% of women received post-surgical adjuvant therapy (9.2% SH and 8.4% RH). With a median follow-up of 4.5 years, 21 pelvic recurrences occurred (11 SH and 10 RH). The PRR3 was 2.52% with SH and 2.17% with RH (difference 0.35% with 95% upper confidence limit 2.32%) in ITT analysis. The 3-year EPRFS and OS were respectively 98.1% and 99.1% with SH; 99.7% and 99.4% with RH. SH had less bladder (9 vs 3) and ureteral injuries (5 vs 3) and significantly less urinary incontinence (4.7% vs. 11.0%; p=0.003) and urinary retention (0.6% vs. 9.9%; p<0.0001) compared to RH. QoL scales with significant difference between the two groups over time were all in favor of SH.

Conclusion The pelvic recurrence rate at 3 years in women with LRESCC who underwent SH was not inferior to RH and was associated with fewer surgical complications and better QoL. SH should be considered the new standard of care.

Disclosures None

#422 CERVICAL MICROBIOTA – POSSIBLE TARGET TO PREVENT CERVICAL CANCER DEVELOPMENT – A PRELIMINARY STUDY

1Krzysztof Nowosielecki, 2Malgorzata Romanik, 3Milosz Matyja, 4Wojciech Szaneczki.

1Department of Gynecological Oncology, University Clinical Center, Medical University of Silesia, Katowice, Poland; 2Department of Medical Microbiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Introduction/Background The aim of this study is to evaluate the presence of specific microbiota in cervical cancer patient material collected from endocervical canal (cervical microbiota). The results will be a basis for further research on cervical cancer co-factors which may stimulate carcinogenesis.

Methodology 20 women diagnosed with cervical cancer independently of FIGO stage, were included in the study. Before the treatment (surgery, CRTH) sample from endocervical canal was collected using cytology brush and preserved in Liquid-Based Cytology container. All collected samples were analyzed to isolate DNA with a NucleoSpin® Tissue kit. DNA isolates were subjected to qualitative and quantitative evaluation, using libraries based on the Illumina-16S Metagenomic Sequencing Library Preparation (16S Sequencing) protocol.

Results The mean age of participant was 54.23 years (range: 32-89 years, median 51 years). Nine women were postmenopausal, eleven were in reproductive age. In both groups bacterial vaginosis associated bacteria (Prevotella spp., Gardnerella vaginalis group, Atopobium vaginae) were dominant part of vaginal microbiota. In two patients in reproductive age with rapid progression and advanced stage Fusobacterium nucleatum was dominating. Interestingly, the prevalence of Ureaplasma spp and Mycoplasma spp in this group was low.

Conclusion In the population of premenopausal women diagnose with cervical cancer presence of Fusobacterium nucleatum in cervical microbiota might be an indicator of rapid progression and poor prognosis. Further studies are need to confirm that observation.

Disclosures None

#601 TERTIARY PREVENTION STRATEGY FOR LOW-VOLUME LYMPH NODE POSITIVE CERVICAL CANCER: SYSTEMATIC REVIEW AND A PROTOTYPE OF ADAPTED MODEL OF CARE

1Marcin Sniadecki, 2Beneditta Guani, 3Paulina Jaworek, 4 Dagmara Klasa-Mazurkiewicz, 5Katia Mahu, 6Karolina Mosakowska, 7Aleksandrew Buda, 8Patryk Poniewierza, 9Maria Stasiak, 10Adrien Cestari, 11Vincent Balaya, 12Karolina Maliszewska, 13Laura Piłat, 14Cynthia Aistei, 15Pawel Guzik, 16Szymon Wydłak, 17Marcin Lio, 18Thomas Gallard, 19Olga Piatak, 20Roman Kocian, 21Zuzanna Chmielewska, 22Damian Wydra. 23Medical University of Gdańsk, Gdańsk, Poland; 24Hospital of Fribourg HFR, Fribourg, Switzerland; 25Institut Curie, Paris, France; 26Michele e Pietro Ferrero Hospital, Verduno, Italy; 27Lazarski University, Warsaw, Poland; 28Hospital Tenon, Paris, France; 29CHUV Lausanne, Lausanne, Switzerland; 30University of Perugia and Perugia General Hospital, Perugia, Italy; 31City Hospital Rzeszów, Rzeszów, Poland; 32Institut Curie, University Paris Cite, Paris, France; 33Charles University, Prague, Czech Republic

Introduction/Background Lymph nodes micrometastases (MICS) are currently key diagnostic and treatment targets in cervical cancer (CC). There is growing evidence that MICS have the